Vor Biopharma (NASDAQ:VOR) Raised to Hold at Wall Street Zen

Vor Biopharma (NASDAQ:VOR) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research analysts have also weighed in on the company. Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $23.03 on Friday. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $50.20. The firm’s 50-day simple moving average is $18.55 and its 200 day simple moving average is $16.01.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Sell-side analysts forecast that Vor Biopharma will post -2.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently bought and sold shares of VOR. China Universal Asset Management Co. Ltd. bought a new position in Vor Biopharma during the fourth quarter valued at $36,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the second quarter valued at $66,000. Chung Wu Investment Group LLC purchased a new position in shares of Vor Biopharma during the 4th quarter valued at $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in shares of Vor Biopharma during the 4th quarter valued at $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma News Roundup

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target to $27. The higher target provides additional support for the stock’s valuation and reflects continued optimism about Vor Biopharma’s long-term prospects. Wedbush Increases Vor Biopharma Price Target to $27.00
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $31 price target. The firm expects continued losses in the near term, including estimated 2027 EPS of negative $3.65, but projects a return to profitability by 2029 at $1.33 EPS. Its estimates imply that the investment case remains dependent on successful clinical and commercial execution.
• Negative Sentiment: HC Wainwright lowered several future earnings forecasts. The firm reduced its Q3 2026 EPS estimate to negative $0.91 from negative $0.70 and its Q4 2026 estimate to negative $0.94 from negative $0.72. It also cut full-year 2027 EPS to negative $3.65 from negative $2.78, full-year 2028 EPS to negative $2.61 from negative $1.67, and full-year 2029 EPS to $1.33 from $1.86. These revisions suggest higher expected losses and a slower path to profitability.
• Negative Sentiment: Recent quarterly results missed expectations. Vor reported a quarterly loss of $0.80 per share versus the consensus estimate of a $0.69 loss, an unfavorable earnings surprise that pressured the stock. Analysts expect the company to remain unprofitable during the current fiscal year. Vor Biopharma Stock Price Down Following Weak Earnings

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).